• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications are not effective for a lot of people suffering from depression. A customized treatment may be the solution.

Cue is an intervention platform for digital devices that transforms passively acquired sensor data from smartphones into customized micro-interventions designed holistic ways to treat depression improve mental health. We analyzed the best-fitting personalized ML models to each subject using Shapley values to discover their feature predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

Depression is a leading cause of mental illness across the world.1 Yet the majority of people with the condition receive treatment. To improve outcomes, doctors must be able to recognize and treat patients who have the highest probability of responding to particular treatments.

The ability to tailor depression treatments is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit the most from specific treatments. They make use of mobile phone sensors as well as a voice assistant that incorporates artificial intelligence and other digital tools. With two grants awarded totaling more than $10 million, they will employ these technologies to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

The majority of research into predictors of depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographics like age, gender, and education, as well as clinical aspects like symptom severity and comorbidities, as well as biological markers.

A few studies have utilized longitudinal data in order to determine mood among individuals. Many studies do not take into consideration the fact that moods vary significantly between individuals. Therefore, it is critical to develop methods that permit the identification of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to detect patterns of behavior and emotions that are unique to each individual.

The team also created a machine-learning algorithm that can identify dynamic predictors of each person's depression mood. The algorithm blends the individual differences to produce an individual "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was low, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied greatly among individuals.

Predictors of symptoms

treating depression is the most common reason for disability across the world1, however, it is often untreated and misdiagnosed. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.

To assist in individualized treatment, it is essential to identify predictors of symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only detect a few features associated with depression.

Machine learning can improve the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements as well as capture a variety of distinct behaviors and patterns that are difficult to document using interviews.

The study involved University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment according to the severity of their morning depression treatment. Patients who scored high on the CAT-DI scale of 35 or 65 were assigned online support via an instructor and those with scores of 75 patients were referred for in-person psychotherapy.

At the beginning, participants answered an array of questions regarding their personal characteristics and psychosocial traits. The questions included age, sex, and education, marital status, financial status as well as whether they divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as how often they drank. Participants also scored their level of residential depression treatment uk severity on a scale of 0-100 using the CAT-DI. The CAT-DI test was performed every two weeks for participants who received online support and weekly for those who received in-person support.

Predictors of Treatment Response

The development of a personalized depression treatment is currently a top research topic and a lot of studies are aimed at identifying predictors that will enable clinicians to determine the most effective medication for each individual. Particularly, pharmacogenetics can identify genetic variants that influence the way that the body processes antidepressants. This lets doctors select the medication that are most likely to work for each patient, reducing the time and effort needed for trials and errors, while avoid any negative side effects.

Another approach that is promising is to create prediction models that combine the clinical data with neural imaging data. These models can be used to determine which variables are the most predictive of a specific outcome, like whether a medication will improve symptoms or mood. These models can be used to determine a patient's response to treatment that is already in place and help doctors maximize the effectiveness of their treatment currently being administered.

A new generation uses machine learning techniques like algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to integrate the effects of several variables and improve predictive accuracy. These models have been proven to be useful in predicting outcomes of treatment for example, the response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the standard for future clinical practice.

In addition to the ML-based prediction models The study of the mechanisms behind depression continues. Recent research suggests that the disorder is connected with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for postnatal depression treatment will be based on targeted treatments that restore normal function to these circuits.

Internet-based interventions are an effective method to achieve this. They can provide more customized and personalized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality of life for MDD patients. Additionally, a randomized controlled study of a personalised treatment for depression demonstrated sustained improvement and reduced adverse effects in a large proportion of participants.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and determining which antidepressant medication will have very little or no adverse negative effects. Many patients are prescribed various medications before finding a medication that is both effective and well-tolerated. Pharmacogenetics offers a new and exciting method of selecting antidepressant drugs that are more effective and precise.

Several predictors may be used to determine which antidepressant to prescribe, such as gene variations, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. However it is difficult to determine the most reliable and reliable factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials of considerably larger samples than those normally enrolled in clinical trials. This is due to the fact that it can be more difficult to detect interactions or moderators in trials that contain only one episode per person rather than multiple episodes over a long period of time.

Additionally the prediction of a patient's response will likely require information about comorbidities, symptom profiles and the patient's own perception of the effectiveness and tolerability. Currently, only a few easily assessable sociodemographic variables and clinical variables are consistently associated with response to MDD. These include age, gender and race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its beginning stages, and many challenges remain. First, a clear understanding of the underlying genetic mechanisms is essential, as is a clear definition of what constitutes a reliable predictor for treatment response. In addition, ethical issues such as privacy and the responsible use of personal genetic information, must be carefully considered. In the long-term the use of pharmacogenetics could be a way to lessen the stigma that surrounds mental health treatment and improve the treatment outcomes for patients with depression. As with any psychiatric approach it is essential to take your time and carefully implement the plan. At present, the most effective course of action is to offer patients a variety of effective depression medications and encourage them to speak with their physicians about their experiences and concerns.